Autologous therapeutic cancer vaccine

This page covers all Autologous therapeutic cancer vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Tumor-associated antigens presented via Hsp96 complexes.

Targets

Tumor-associated antigens presented via Hsp96 complexes

Phase 3 pipeline (1)

• HSPPC-96 or Oncophage · Agenus Inc. · Oncology
  HSPPC-96 is a personalized cancer vaccine that uses heat shock protein-peptide complexes derived from a patient's own tumor to stimulate immune recognition and destruction of cancer cells.

Patent intelligence

• autologous therapeutic cancer vaccine patent landscape — aggregated cliff calendar, attackable patents, originator estates